A Single-Center, Open-Label, Randomized, Crossover Design Study to Evaluate the Effect of Dietary Status on Pharmacokinetic Profile of Orally Administered First-Line Anti-TB Drugs in Subjects With Pulmonary Tuberculosis.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ethambutol; Rifampicin/isoniazid/pyrazinamide
- Indications Pulmonary tuberculosis
- Focus Pharmacokinetics
- Acronyms TBPK
- 12 Apr 2011 Biomarkers information updated
- 12 Feb 2010 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.